Hawaii Clinical Trials Report — June 2026

For Hawaii residents exploring opportunities in clinical research, June 2026 presents a critical window to act on several studies nearing their conclusion. A total of 9 clinical trials across the islands are set to close within the next 90 days, meaning interested participants have a limited time to enroll. Among these, 2 trials are still actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also be aware of these impending deadlines. Research focusing on various cancers, neurological disorders, and metabolic conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer
• Cancer
• Chemotherapy induced peripheral neuropathy (CIPN)
• Chronic inflammation
• Colon cancer
• HIV
• Lung cancer
• Multifocal motor neuropathy
• New onset generalized myasthenia gravis (gMG)
• Obesity and overweight

These studies represent diverse areas of medical inquiry, from oncology to neurology, and their closure signifies a narrowing opportunity for patients to access these specific investigational treatments or contribute to understanding these conditions.

A Significant New Opportunity for Weight Management Research

This month, Hawaii welcomes 1 new clinical trial, matching the single trial that opened in May 2026. While the number of new studies is modest, this particular addition is a notable Phase 3 drug trial from a major industry sponsor, focusing on a widespread health challenge.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global study aims to enroll 3,600 participants and is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study. It will investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily compared with placebo, when used in combination with a reduced-calorie diet. This trial is specifically designed for individuals with obesity or overweight conditions who also have a weight-related comorbidity, offering a promising new avenue for chronic weight management.

This new trial is a drug intervention and is sponsored by an industry leader, highlighting the ongoing commitment to developing new treatments for metabolic health. It is currently recruiting in Honolulu, making it accessible to residents in the state's most populous city.

Healthy Volunteer Opportunities and Participant Demographics

While the single new trial this month does not accept healthy volunteers, there remain ample opportunities for individuals without specific medical conditions to contribute to research across Hawaii. Currently, a total of 25 clinical trials statewide are actively seeking healthy participants. These studies play a crucial role in establishing baseline data and understanding drug effects in healthy populations, making their contribution invaluable.

The new trial for obesity and overweight is inclusive of older adults, ensuring that research benefits a broad range of age groups. None of the new trials are exclusively for females or males, nor do they specifically include children, focusing instead on the adult population for this particular weight management study.

Hawaii's Research Landscape: Geographic Reach and Accessibility

Hawaii's clinical research ecosystem remains active, with a total of 209 clinical trials currently recruiting across 16 cities and 100 research sites statewide. This broad distribution ensures that residents in various regions of Hawaii have access to cutting-edge research, even if the primary concentration of new trials tends to be in metropolitan areas.

This month's new trial is located in Honolulu, which is a central hub for medical research and healthcare services in the state. While Honolulu often sees the highest concentration of new studies, the overall number of recruiting trials across 16 cities indicates a commitment to making research accessible beyond the capital.

Looking Ahead in Hawaii's Clinical Research

The trend for new trial openings in Hawaii has seen 1 new trial in June, consistent with May's single opening. Over the past 6 months, the number of new trials has fluctuated, with 4 in January, 3 in February, 3 in March, and 3 in April. This month's significant Phase 3 trial for obesity and overweight represents a key development in a high-need area.

As we move forward, the focus will remain on the ongoing enrollment in the new weight management study and the critical, time-sensitive opportunities in trials nearing their conclusion. Residents are encouraged to explore these options and consider contributing to the advancement of medical knowledge in Hawaii.